2024;18(3):e32050
Known in scientific literature as a triple-receptor agonist, Retatrutide acts simultaneously on three distinct metabolic hormone pathways: the Gastric Inhibitory Polypeptide (GIP) receptor, the Glucagon-Like Peptide-1 (GLP-1) receptor, and the Glucagon (GCG) receptor
After 24 weeks, all groups taking retatrutide saw significant weight loss compared to the placebo group (1.6% average weight loss): 7.2% for those taking 1 mg 11.8% for those taking 4 mg after starting with 2 mg 13.9% for those taking 4 mg after starting with 4 mg 16.7% for those taking 8 mg after starting with 2 mg 17.9% for those taking 8 mg after starting with 4 mg 17.5% for those taking 12 mg after starting with 2 mg After 48 weeks, patients taking retatrutide experienced even more substantial losses: 8.7% for those taking 1 mg 16.3% for those taking 4 mg after starting with 2 mg 17.8% for those taking 4 mg after starting with 4 mg 21.7% for those taking 8 mg after starting with 2 mg 23.9% for those taking 8 mg after starting with 4 mg 24.2% for those taking 12 mg after starting with 2 mg The researchers also reported that 100% of patients taking 8 mg or 12 mg saw a weight reduction of at least 5%, and 7583% had a weight reduction of 15% or more
Aseptic technique: Always use aseptic technique when withdrawing doses
Behav Brain Res 348:7481 Jastreboff AM, Kaplan LM, Fras JP et al (2023) Triplehormone-receptor agonist Retatrutide for obesitya phase 2 trial
Missing doses or inconsistent timing can reduce effectiveness and slow weight loss progress
